Business Wire

IQM-QUANTUM-COMPUTERS

21.12.2021 12:02:08 CET | Business Wire | Press release

Share
IQM Continues Its European Expansion; New French Subsidiary Will Focus on IQM’s Co-design Customers in Aviation, Space, and Cybersecurity.

IQM France will collaborate closely with customers in the aviation, space, and cybersecurity verticals using IQM’s co-design approach. IQM is also part of Atos’s Scaler program, and this subsidiary will focus further on HPC integration and offer quantum accelerators to supercomputing centers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005096/en/

Through this new subsidiary, IQM joins the French quantum ecosystem that consists of world-renowned universities and research institutes and a fast-growing start-up scene and provides excellent industry infrastructure. IQM’s expertise and reach, combined with this vibrant ecosystem, will create significant opportunities for partnerships and collaboration in Europe and across the globe.

In the first phase, IQM France aims to tap into the extended talent pool of quantum students, postdocs, and experienced professionals. The plan is to start with a core team of business developers, products managers, quantum scientists, and engineers in 2022. The aim is to create a center of excellence in specific industry verticals and systematically grow in subsequent years.

IQM France’s office will be in the central hub at Spaces Les Halles on 40 rue du Louvre, Paris. Dr. Björn Pötter will take on the role of Country Manager for France in addition to his role as Global Head of Products at IQM. Dr. Pötter, who recently joined IQM, holds a PhD in physics and has extensive experience with digital technologies in the Aerospace and Cybersecurity industries. Dr. Pötter has held several international leadership positions with a focus on technology and innovation, among others at Airbus.

“I am excited to see IQM start its French operations in the Paris region, where I have been working for several years. The Paris team will build the bridge between the various IQM teams around Europe and the high-quality French quantum ecosystem. The team will enable local operations for collaborative IQM projects in strategic industrial areas,” said Dr. Pötter.

Speaking about this announcement, Dr. Jan Goetz, CEO and cofounder of IQM, said, “France plays an integral role in the quantum scientific research and has been on our roadmap for a while. I’m extremely pleased to announce the operations of our French entity today, especially at a time when the French quantum plan is gaining momentum. This French subsidiary together with our co-design teams in Bilbao and Munich and the quantum hardware and software teams in Espoo, Finland, will strengthen European quantum leadership.”

“The Paris region is proud to welcome a major European quantum computing player to the epicenter of the French quantum ecosystem. We support IQM’s local setup and growth to help them make the most of the excellent research and talent available. We are also convinced that IQM will thrive in France’s #1 aerospace region,” said Alexandra Dublanche, President of Choose Paris Region and Vice President in charge of Recovery, Attractiveness, Economic Development, and Innovation of the Paris Region.

“We are very thankful to Choose Paris Region and also Business France for the active, pragmatic, and timely support, which allowed us to set up IQM France in a very short time,” Dr. Pötter added.

In March 2021, Dr. Goetz presented on deep tech and building global tech leaders’ topics at the Scale-Up Europe event, where President Emmanuel Macron was an attendee. This presentation was part of the Scale-up Europe initiative facilitated by Sifted.

About IQM Quantum Computers:

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers the quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building a quantum computer in Germany that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich, and Espoo and employs over 130 people. More information: www.meetiqm.com

Links to the quoted press releases:

  • IQM opens its exclusive quantum fabrication facility in Finland
  • IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
  • IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.

Registered office:

IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland

Choose Paris Region is the agency in charge of promoting the attractiveness of the Paris region in terms of international business. The agency works in partnership with all the region’s key players to create an appealing and coherent territorial offer, ensure promotion of the region, and offer a tailor-made service to support international businesses and professionals in their expansion.

https://www.chooseparisregion.org/

Headquarters:

Choose Paris Region, 18 rue de Londres, 75009 Paris

contact@chooseparisregion.org - +33 800 019 011

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye